ANRO
ANRO clinical trials: Alto Neuroscience, Inc.
Every trial on ClinicalTrials.gov where Alto Neuroscience, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 12
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
ANRO on the catalyst calendar · ANRO registry changes
- Primary completion Nov 2027Sponsor estimatePhase 2NCT07553637ALTO-207 in Adults With Treatment-resistant Depression (TRD)Alto Neuroscience · Treatment-resistant Depression (TRD)RecruitingANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05922878Study of ALTO-300 in MDDAlto Neuroscience · Major Depressive DisorderRecruitingANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 2NCT06656416ALTO-100 in Bipolar Disorder With Depression (BD-D)Alto Neuroscience · Bipolar Disorder I or II With a Major Depressive EpisodeRecruitingANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 14, 2025ActualPhase 2NCT06391593PD, PK, and Safety of ALTO-203 in Patients With MDDAlto Neuroscience · Major Depressive DisorderCompletedANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2026Sponsor estimatePhase 2NCT06502964Study of ALTO-101 in Patients With SchizophreniaAlto Neuroscience · SchizophreniaRecruitingANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 5, 2024ActualPhase 2NCT05712187Phase 2b Study of ALTO-100 in MDDAlto Neuroscience · Major Depressive DisorderCompletedANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 5, 2023ActualPhase 2NCT05118750ALTO-300 in DepressionAlto Neuroscience · Major Depressive DisorderCompletedANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 26, 2023ActualPhase 2NCT05157945ALTO-300 in Depression (ALTO-300-004)Alto Neuroscience · Major Depressive DisorderCompletedANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 13, 2023ActualPhase 2NCT05419869Pilot Decentralized TrialAlto Neuroscience · Major Depressive DisorderCompletedANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2022ActualPhase 2NCT05117632ALTO-100 in MDD and/or PTSDAlto Neuroscience · Major Depressive DisorderCompletedANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2023Sponsor estimatePhase 4NCT04388202Leveraging EEG for Antidepressant Prediction With Sertraline and EscitalopramAlto Neuroscience · Major Depressive DisorderWithdrawnANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2023Sponsor estimatePhase 4NCT04388189Leveraging EEG for Antidepressant Prediction With Duloxetine and BupropionAlto Neuroscience · Major Depressive DisorderWithdrawnANROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner